Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.
Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
Drugs to be Discontinued
Recent Gains in Clinical Multiple Sclerosis Research Review.
The effect of supported standing in adults with upper motor neurone disorders: a systematic review.
Association of multiple sclerosis susceptibility variants and early attack location in the CNS.
Drug record: Amiloride
Deep 3D Convolutional Encoder Networks with Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Cognitive and Behavioral Outcomes in Individuals With a History of Acute Disseminated Encephalomyelitis (ADEM).
Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event.
Interpretation and visualization of non-linear data fusion in kernel space: study on metabolomic characterization of progression of multiple sclerosis.
New Drug Review 2010: Ustekinumab (Stelara, Centocor Ortho Biotech)
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Transcriptional enhancers: from properties to genome-wide predictions.
Substance Name: Naltrexone
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis.
IFN-γ Signaling to Astrocytes Protects from Autoimmune Mediated Neurological Disability.
Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis.
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
Physiotherapy as an immunoactive therapy? A pilot study.

Pages